Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain

Keyphrases

• Kinase Inhibitor 100%
• Spectroscopic Analysis 100%
• Bosutinib 100%
• Tyrosine Kinase Domain 100%
• Abl Tyrosine Kinase 100%
• Chronic Myeloid Leukemia 60%
• Imatinib Resistance 40%
• Clinical Trials 20%
• Fusion Protein 20%
• Abl Kinase 20%
• Chemical Compounds 20%
• BCR-ABL 20%
• Imatinib 20%
• Dasatinib 20%
• Src Kinase 20%
• Kinase Activity 20%
• Structural Characterization 20%
• Binding Mode 20%
• Spectroscopic Characterization 20%
• Kinase Domain 20%
• Inhibitor Activity 20%
• Resistant mutants 20%
• Enhanced Selectivity 20%
• Nilotinib 20%
• Clinical Problems 20%
• Nitriles 20%
• ATP Binding Site 20%
• Infrared Absorption 20%
• Fluorescence Property 20%
• Inhibitor Binding 20%
• Nitrile Group 20%
• T315I mutation 20%
• Selling 20%

Biochemistry, Genetics and Molecular Biology

• Tyrosine Kinase 100%
• Bosutinib 100%
• Phosphotransferase 100%
• Kinase 100%
• Receptor Tyrosine Kinase 100%
• Myeloid 60%
• Imatinib 60%
• Infrared Radiation 20%
• Clinical Trial 20%
• Absorption 20%
• Binding Site 20%
• Adenosine Triphosphate 20%
• Dasatinib 20%
• Chimeric Protein 20%
• Nilotinib 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphotransferase Inhibitor 100%
• Abelson Kinase 100%
• Bosutinib 100%
• Chronic Myeloid Leukemia 60%
• Imatinib 60%
• Nitrile 40%
• Phosphotransferase 40%
• Clinical Trial 20%
• Binding Site 20%
• Dasatinib 20%
• Nilotinib 20%
• Chimeric Protein 20%
• Adenosine Triphosphate 20%